Abstract
Background
Motion sickness arises from sensory conflict between visual, vestibular, and somatosensory inputs, causing nausea, dizziness, and vomiting. Non-pharmacological interventions are underexplored despite their potential for accessibility and safety. This study evaluated (1) Computer-Assisted Rehabilitation Environment (CAREN) as a novel tool to induce motion sickness and (2) the efficacy of fluid-filled motion sickness glasses which create an artificial horizon to counteract peripheral visual-vestibular mismatch and reduce symptoms.
Methods
A randomized controlled trial was conducted with thirty motion sickness–susceptible participants (23 females, 7 males; median age 34.2 years). Participants were exposed to a standardized “scrambler” ride simulation via CAREN, which combined vestibular and visual motion stimuli. The intervention group (n = 15) wore fluid-filled frames, while the placebo group (n = 14) wore identical glasses with drained fluid. Symptoms were assessed pre/post using the Motion Sickness Assessment Questionnaire (MSAQ) and every 60 s during exposure using the Motion Illness Symptoms Classification (MISC) scale. Wilcoxon signed-rank and Mann-Whitney U tests compared outcomes.
Results
CAREN significantly induced motion sickness, with median MSAQ scores increasing from 17.0 (IQR: 16.0–19.0) pre-exposure to 40.5 (IQR: 27.0–57.0) post-exposure (p < 0.001). No significant difference was observed between intervention and placebo groups in symptom reduction (median MSAQ increase: 31.0 vs. 16.0, p = 0.15) or glasses-wearing duration (p = 0.89).
Conclusions
CAREN reliably induced motion sickness, supporting its utility for controlled research. However, the motion sickness glasses did not significantly alleviate symptoms compared to placebo in this pilot study. It is possible that peripheral visual cues from fluid-filled glasses may be insufficient to counteract sensory mismatch. Further research should explore larger sample sizes and alternative non-pharmacological interventions using CAREN’s controlled environment.
Trail registration: This trial was not prospectively registered in a public registry as it was a limited internal study within the Midwestern University community. The study received ethical approval from our Institutional Review Board (IRB #24–0155), and informed consent was obtained from all participants.
Keywords: Motion sickness, Virtual reality, Rehabilitation technology, Sensory conflict, Wearable devices, Postural control, Computer-assisted rehabilitation environment (CAREN), Nonpharmacological intervention
Introduction
Motion sickness is a common condition that may arise when an individual’s visual, vestibular, and somatosensory inputs send conflicting messages to the brain, resulting in a sensation of false movement. This may lead to symptoms of dizziness, nausea, sweating, pallor, headache, hyperventilation, vomiting, and anxiety [1]. Motion sickness is often associated with travel, whether by air, land, or sea, where there is a discrepancy between visual stimulation and perceived movement. Since the severity of symptoms varies across individuals, those who are more sensitive to motion sickness are prone to experiencing difficulties with travel. Owing to the considerable impact of motion sickness on individuals, treatment has traditionally relied on pharmacological interventions—both over the counter and prescription medications—that often suppress vestibular system function. However, there remains a notable gap in the literature regarding effective nonpharmacological approaches for managing motion sickness symptoms, highlighting the need for further research in this area. This study aims to investigate nonpharmacological treatment options that are accessible, feasible, and cost-effective for public use.
Motion sickness demographics and risk factors
Certain people are more prone to experiencing motion sickness, with research highlighting age and sex as significant risk factors. The demographics of those who experience motion sickness are often women and children [1]. Children between the ages of 6 and 12 years are more susceptible because of their developing vestibular systems and greater sensitivity to sensory conflicts. Compared with men, women also demonstrate increased vulnerability, a trend that may be influenced by hormonal fluctuations, particularly during menstruation, pregnancy, or the use of hormonal contraceptives, all of which are associated with heightened motion sensitivity [1]. These demographics demonstrate the increased need to identify a motion sickness intervention that is safe for women and children.
In addition to individual factors, the mode of travel plays a substantial role in the incidence of motion sickness. Maritime transport poses a particularly elevated risk, with one study reporting that up to 62.1% of passengers experience motion sickness during boat or ship travel [2]. The unpredictable and multidirectional motion of watercraft exacerbates sensory mismatch, making this mode of travel especially challenging for susceptible individuals.
Motion sickness during air travel is a significant concern, affecting a substantial portion of passengers despite the typically lower motion intensity compared with maritime travel. Research has demonstrated that approximately 8.4% of passengers on regional or domestic flights report nausea, with 0.5% experiencing vomiting, particularly in response to low-frequency vertical and lateral aircraft movements [3]. Another source estimates that up to 24% of airline passengers experience symptoms of nausea or general discomfort during flights, highlighting the variability in susceptibility and the influence of factors such as seating position, turbulence, and pretravel behaviors [4]. The incidence of air sickness among student aviators in the U.S. and German Air Forces ranges from 10% to 20%, suggesting that physiological and vestibular sensitivity can persist despite repeated exposure and training [5]. The findings above using different modalities to travel underscore the need for targeted, evidence-based strategies to prevent and manage motion sickness, particularly for vulnerable populations.
In the context of the present study, the prevalence of motion sickness on roller coasters and amusement park rides is notably high. Although few studies have directly examined the induction of motion sickness symptoms in these settings, one investigation utilized the Motion Sickness Symptoms Questionnaire Short Form (MSSQ-SF) to assess reported experiences across various environments [6]. The findings indicated that 39.1% of children and 42.1% of adults experienced motion sickness specifically on roller coaster rides [6]. Furthermore, 43.7% of adults reported experiencing motion sickness on Ferris wheels—the highest prevalence among all surveyed modes of transportation, including cars, buses, planes, trains, and maritime travel [6]. These results underscore the significance of amusement park rides as a potential context for motion sickness and support the rationale for employing a scrambler ride simulation in a semi-immersive VR environment to experimentally induce motion sickness. Cybersickness (CS), a visually induced form of motion sickness experienced in virtual environments, has been widely studied. However, the current study differs in that motion was induced through both visual and physical platform movement, potentially eliciting a distinct sensory mismatch compared with standard CS.
The vestibulo-ocular reflex
Motion sickness disrupts the ability of the brain to maintain spatial orientation—a process in which the vestibulo-ocular reflex (VOR) plays a vital role. The VOR is an extremely smooth and precise reflex responsible for stabilizing vision during both planned and unplanned head movements. Stabilization of vision is accomplished by the VOR, which integrates vestibular input to signify head movement and direct eye movement in the opposite direction. The vestibular nerve (part of cranial nerve VIII) communicates with the vestibular nucleus and cerebellum. From the vestibular nucleus, the signal travels to the extra ocular muscle (EOM) nucleus and the paramedian pontine reticular formation (PPRF) through the medial longitudinal fasciculus (MLF) to coordinate eye movements in response to head movements. Horizontal movement signals travel from the PPRF to cranial nerve VI and cranial nerve III nuclei, whereas vertical movement signals travel from the rostral interstitial nucleus of the MLF to the oculomotor nerve (cranial nerve III) and the trochlear nerve (cranial nerve IV) nuclei and to relevant EOMs.
As suggested by Cohen et al., the peripheral visual stimuli that activate the visual system are projected to the brainstem, cerebellum, inferior olives, vestibular nuclei, and Purkinje cells in both the nodules and the flocculus [7]. The same peripheral visual stimuli do not travel through the cortical visual system, including the lateral geniculate body, where a vast majority of visual information travels. Head motion (relative to gravity) and peripheral visual input traveling to the brainstem and cerebellum are critical parts of the generation of motion sickness symptoms. Research suggests that vertical oscillation of horizontal lines does not cause motion sickness when presented with a central visual field but has a potent effect on creating motion sickness symptoms when presented in the periphery [8]. Full-field visual motion that involves a naso‒occipital axis includes the central field inputs to the lateral geniculate nucleus and calcarine cortex. Theoretically, vertical oscillating motion that stimulates the periphery of the visual field in turn stimulates roll around the naso-occipital axis, which then provides the vestibular system with motion sickness.
Current studies and treatment
Alternative nonpharmaceutical options, such as alcohol wipes and ginger, have been shown to be effective countermeasures for decreasing motion sickness symptoms such as nausea. Isopropyl alcohol wipes have been shown to be effective at relieving nausea symptoms within 10 min of treatment in the emergency department (ED). Research has shown that implementing isopropyl alcohol in the ED is an effective and practical first-line treatment for alleviating nausea [9, 10]. Ginger has been used for a variety of treatments because of its medicinal properties. Lien et al. reported that ginger can be used in the prevention and treatment of motion sickness due to its ability to “reduce nausea, tachygastric activity, and vasopressin release from the circular vection [11].” A study by Flanagan et al. revealed that motion sickness symptoms can be reduced by visual fixation; however, a greater decrease in symptoms is apparent when ginger is combined with field of view (FOV) restriction [12].
In recent years, motion sickness glasses have been introduced to reduce the symptoms of motion sickness quickly without the use of medication. The motion sickness glasses used during this experiment were manufactured by Hion™ and have four liquid-filled circular frames without lenses. Two circular frames in front and one on each side cover the user’s periphery. As the user moves, the liquid shifts to create an artificial horizon, aiming to realign visual and vestibular input. The manufacturer claims that glasses reduce motion sickness across various travel settings, including cars, planes, and boats. Recommended use involves focusing on a stationary object, such as a book or phone, while wearing Hion™ glasses for 10–14 min, and symptoms are claimed to subside. The current study methods were designed to closely replicate the manufacturer’s suggested use and evaluate the manufacturer’s claim that motion sickness glasses reduce symptoms within a 14-minute timeframe.
Over the past two decades, the use of virtual reality (VR)-based rehabilitation has transitioned from the development of the technology itself to rehabilitation research and clinical applications, as suggested by Keshner et al. [13]. A newer application of VR-based rehabilitation is the computer-assisted rehabilitation environment (CAREN), which is widely used for clinical applications such as gait training, balance dysfunctions, and optokinetics. Keshner et al.l. alluded to VR-based rehabilitation transitioning to an intervention rather than an expansion of the technology itself, and their prediction sets the basis of this study [13]. CAREN uses advanced biomedical technology to simulate real-life scenarios, which allows for standardization.
Aims of the study
A comprehensive understanding of motion sickness requires controlled induction to observe symptom presentation and evaluate potential interventions. However, there remains a notable gap in the literature regarding standardized and reliable methods for inducing motion sickness in experimental settings, which limits the advancement of research in this area. This pilot study induces motion sickness in participants using a semi-immersive virtual reality environment, the CAREN. This study aims to address this gap in the literature by developing a consistent protocol to induce motion sickness via CAREN.
This two-part study aims to (a) determine whether CAREN can reliably induce motion sickness symptoms and (b) evaluate the effectiveness of motion sickness glasses as a nonpharmacological treatment option that is accessible, feasible, and cost-effective for public use.
Methods
We conducted a randomized controlled trial in which the intervention group was provided Hion™ brand motion sickness glasses, whereas the placebo group was provided identical glasses with fluid drained from all four circular frames. A needle was used to drain the liquid to reduce any obvious signs of tampering, followed by the addition of compressed air to remove any residual liquid. Our biomedical engineer and CAREN operator were able to create a simulated ‘scrambler’ theme park ride to be used on the CAREN to induce symptoms of motion sickness in a controlled, consistent, and reproducible manner. Prior to the selection of study participants, we collaborated with a statistician to determine the quantity of participants needed to create sufficient statistical power to detect a medium-to-large effect size. The resulting sample size for both study aims was a minimum of thirty participants.
Participants
A total of 30 participants (23 females, 7 males, median age: 34.2 years) were recruited via a flyer that was sent to all the students and faculty at Midwestern University in Glendale, Arizona, in addition to the neighboring community. Participants who met the eligibility criteria were instructed to contact the research staff for prescreening. No compensation was offered to the participants, as they were volunteers assisting in our research collection. The inclusion and exclusion criteria were as follows:
Inclusion criteria
The inclusion criteria were as follows: (1) participants must be available for approximately two consecutive hours for this study; (2) have a history of motion sickness; (3) be at least 18 years of age; (4) weigh fewer than 300 pounds; (5) wear athletic clothing and closed toe shoes for the entire duration of the study; (6) be able to stand independently for 30 min; (7) are responsible for bringing their own medication to use after the study is completed, as part of our safety protocol, and must meet the motion sickness criteria, which include (a) having at least five episodes of motion sickness caused by the same or similar stimuli of motion; (b) signs or symptoms are reliably reproducible by the same or similar motion stimuli; (c) symptoms do not improve with repeated exposure to the same or similar motion stimuli; (d) signs or symptoms cause the patient to change their behavior by activity modification, avoidance, or aversive emotions to expected motion stimulus; and (e) signs or symptoms are not better accounted for by another disease or disorder. Patient informed consent was obtained prior to starting any information collection and CAREN session.
Exclusion criteria
The exclusion criteria for participants were as follows: (1) cannot have taken motion sickness or nausea medication within the past week prior to the study; (2) must not have a history of any conditions that can affect balance, which includes the following: (a) neurologic (e.g., Parkinson’s disease, stroke, neuropathy-decreased sensation in one’s feet, traumatic brain injury); (b) surgical (e.g., recent leg, pelvic, or back surgery); (c) musculoskeletal (e.g., sprained ankle, strained muscle, or painful bunion); (d) visual (e.g., altered vision, unable to see fully even with corrected lenses, depth perception issues); and (e) perceptual (e.g., vestibular issues such as vertigo, Meniere’s disease). If the participants met the criteria, they were allowed to participate in the study, and a date was scheduled for their appointment with researchers and the CAREN.
CAREN set up
The Computer Assisted Rehabilitation Environment (CAREN; Motek Medical, Amsterdam, The Netherlands) is a semi-immersive virtual reality system that combines visual projection and physical motion. It consists of a 180° cylindrical screen that surrounds the user’s visual field while allowing partial visual reference to the real environment, which helps reduce cybersickness. Participants stood on a motion platform mounted on a six-degree-of-freedom motion base capable of translating and rotating in all directions. During the current experiment, the platform moved in a circular trajectory along the horizontal plane while simultaneously rotating about the vertical (yaw) axis. Although the motion base’s range of movement was physically constrained and did not fully replicate the complete virtual motion (e.g., continuous 360° rotation), its motion was precisely synchronized with the camera movement in the virtual scene to maintain visual–vestibular correspondence.
CAREN simulation
After being selected for the study, participants were instructed to check in with front office staff at the Midwestern University physical therapy institute and wait in the lobby until research staff called for them. They were taken into an examination room to review a copy of the consent documentation and provided adequate time to ask any questions before transitioning to CAREN testing. The participants were informed that because of the aims of this study, inducing symptoms of motion sickness was to be expected, and they may withdraw from the study at any time. The participants were also instructed to fill out a motion sickness assessment questionnaire (MSAQ) to ensure that they were not experiencing any motion sickness symptoms prior to their time on the CAREN. If they consented to continue with the study, they were directed to the room that holds the CAREN, and vital parameters, including heart rate, blood pressure, and oxygen saturation, were recorded while they were sitting. The participants were then secured in a harness for safety, escorted onto the platform, and then hooked into the CAREN’s built-in support system, which was rated to hold 300 pounds per our inclusion criteria.
At this point, the lights were dimmed, and the biomedical engineer responsible for operating the CAREN provided the participant with either the placebo or intervention motion sickness glasses attached via an eyewear retainer. The operator informed the participants that they were allowed to use the handrails as much or as little as they would like, and if they became too nauseous, an emesis receptacle was behind them.
After confirming that there were no further questions from the participants and that they were ready to begin, the scrambler simulation began. The program implemented on the CAREN offered visual and motion stimulation, as the movements on the screen were carefully calibrated to best match the movements of the platform to mimic the scrambler ride as artificially and controlled as possible. The participants’ symptoms were then assessed every 60 s via the Motion Illness Symptoms Classification Scale (see the instruments section below). Upon completion of the CAREN simulation, participants were taken off the platform, and vital participants were reassessed while sitting. They were then provided another MSAQ, which was recorded as the post-CAREN MSAQ score. The participants were reminded that they could take any medication that was brought with them to aid in reducing their symptoms, and water, ginger, and alcohol wipes were available upon request.
Instruments
The MSAQ (Fig. 1), a self-reported clinical tool that assesses the severity of motion sickness symptoms, was used before and after simulation. This questionnaire quantifies motion sickness through a multidimensional lens, as motion sickness comprises a collection of symptoms that can be categorized into four different sets: gastrointestinal, central, peripheral, and sopite-related [14]. The MSAQ has established validity, as scores from this questionnaire strongly correlate with scores taken from the Pensacola Diagnostic Index (PDI) and the Nausea Profile (NP), making it a valid tool for quantifying motion sickness severity [14]. Furthermore, a score of 30 or below on the MSAQ was used as the cutoff score for allowing participants into the study. This score would place the participants slightly above “a mild severity” (24) [14], providing a buffer in the event where participants felt irritated or tired, still permitting their entry into the study. In addition, a post-MSAQ score of 30 or below was used to assess participants’ readiness to safely leave the simulation.
Fig. 1.

Motion Sickness Assessment Questionnaire (MSAQ) [14].
The Motion Illness Symptoms Classification Scale or Misery Scale (MISC) — an 11-point scale ranging from 0 (no symptoms) to 10 (vomiting) — was used to assess motion sickness symptoms each minute while the participants were on the CAREN [15]. Owing to its instantaneous results, the MISC is an efficient tool used to assess the progression of symptoms [15]. The MISC was adapted into a picture form to display while on the CAREN platform to provide a visual representation (Fig. 2). A score of 5 on the MISC was used as the starting point when the participants were given glasses, as this score was the point when they would feel moderate to severe dizziness [16]. Finally, a cutoff score of 7 was used as the termination point of the simulation, as this is the point immediately before severe nausea [17].
Fig. 2.
Motion Illness Symptoms Classification Scale or Misery Scale (MISC) [15].
Safety protocol
The participants were instructed to bring any personal medication they typically use to manage motion sickness symptoms to be used at their discretion following the simulation. In addition, nonpharmaceutical remedies, including ginger chews and alcohol wipes, were made available onsite. Bottled water was provided for all the participants. After the simulation, individuals were given the option to recover in a quiet, dimly lit room furnished with various seating options for comfort. The participants were also permitted to step outside for fresh air if they believed it would aid in alleviating any lingering symptoms of motion sickness.
Statistical methods
Pre-CAREN baseline measurements and preintervention measures are summarized as medians and interquartile ranges (IQRs) for the intervention and placebo groups. Mann‒Whitney U tests were used to evaluate balance across comparison groups.
For our primary aim, the CAREN’s ability to induce motion sickness was assessed by comparing pre- versus post-CAREN median MSAQ scores for the full cohort. The Wilcoxon signed-rank test, with Benjamini & Hochberg adjustment for multiple comparisons, was used to assess significant changes in median MSAQ scores. We reported the median and IQR for each timepoint along with the adjusted p value.
For our secondary aim, we stratified our cohort by placebo and intervention and compared pre- and post-CAREN median MSAQ scores. Within-subject effects were assessed via the Wilcoxon signed-rank test, whereas between-subject effects were assessed via the Mann–Whitney U test. P values for both comparisons were adjusted for multiple testing via the Benjamini & Hochberg adjustment, and we reported the median and IQR for each timepoint. We also compared the duration of glasses in minutes across the comparison groups via the Mann–Whitney U test. Finally, pre- and postintervention MISC values stratified by comparison groups were visually displayed via spaghetti plots.
All the statistical tests were two-sided, and p values < 0.05 after adjustment were considered statistically significant. SAS version 9.4 (SAS Institute, Cary, NC) was used for all data cleaning and analyses.
Results
A total of thirty participants met the inclusion criteria and were initially included in the study. One subject was excluded from the analysis because of a lack of adequate motion sickness symptoms from CAREN stimulation. At baseline, the intervention (n = 15) and placebo (n = 14) groups were similar in terms of age (p = 0.56), systolic (p = 0.35) and diastolic blood pressure (p = 0.29), heart rate (p = 0.32), and SpO₂ (p = 0.53). Preintervention comparisons, including pre-MSAQ scores (p = 0.81), minutes without glasses (p = 0.77), and mean MISC scores (p = 0.71), also revealed no significant differences between groups (Table 1).
Table 1.
Descriptive statistics stratified by intervention arm (n = 29)
| Intervention (n = 15) | Placebo (n = 14) | p valuea | |
|---|---|---|---|
| Pre-CAREN Measures, median (IQR) | |||
| Age | 28.0 (24.0, 40.0) | 29.0 (26.0, 33.0) | 0.56 |
| Systolic Blood Pressure | 128.5 (116, 138.0) | 121.5 (114.0, 129.0) | 0.35 |
| Diastolic Blood Pressure | 85.5 (75.0, 90.0) | 79.5 (73.0, 85.0) | 0.29 |
| Heart Rate | 75.0 (65.0, 83.0) | 70.5 (65.5, 75.0) | 0.32 |
| SPO2 | 99.0 (98.0, 99.0) | 99.0 (98.5, 99.0) | 0.53 |
| Pre-Intervention Measures, median (IQR) | |||
| preMSAQ | 17.0 (16.0, 19.0) | 17.5 (16.0, 21.0) | 0.81 |
| Minutes Without Glasses | 7.0 (5.0, 9.0) | 7.0 (3.0, 10.0) | 0.77 |
| Mean Misc Scores (Pre-Caren) | 3.43 (3.14, 3.88) | 3.34 (2.89, 4.00) | 0.71 |
a Mann‒Whitney U test
The CAREN score significantly increased (p < 0.001) the MSAQ score in the full cohort. The median pre-CAREN MSAQ score was 17.0 (IQR: 16.0, 19.0), whereas the post-CAREN median score was 40.5 (IQR: 27.0, 57.0) (Table 2).
Table 2.
Pre- versus post-CAREN MSAQ scores for the full cohort (n = 29)
| Pre-CAREN MSAQ | Post-CAREN MSAQ | Difference | p valuea | |
|---|---|---|---|---|
| Full Cohort | 17.0 (16.0, 19.0) | 40.5 (27.0, 57.0) | 21.0 (9.0, 39.0) | < 0.001 |
a Wilcoxon signed-rank test with Benjamini & Hochberg adjustment for multiple comparisons
Both the placebo and intervention groups presented significant increases (p = 0.001 and p < 0.001, respectively) in median MSAQ scores. The placebo group had a median increase of 16.0 (IQR: 9.0, 29.0), whereas the intervention group had a median increase of 31.0 (IQR: 16.0, 45.0). No significant difference was detected in the change in MSAQ score between the placebo group and the intervention group (p = 0.15) (Table 3). The glass duration during CAREN exposure did not significantly differ between the groups (p = 0.89) (Table 4).
Table 3.
Pre- versus post-CAREN MSAQ scores stratified by intervention arm (n = 29)
| Pre-CAREN MSAQ | Post-CAREN MSAQ | Difference | p valuea | |
|---|---|---|---|---|
| Within-Subject Effects | ||||
| Comparison Groups | ||||
| Placebo | 17.5 (16.0, 21.0) | 38.0 (25.0, 45.0) | 16.0 (9.0, 29.0) | 0.001 |
| Intervention | 17.0 (16.0, 19.0) | 50.0 (33.0, 64.0) | 31.0 (16.0, 45.0) | < 0.001 |
| Between-Subject Effects | ||||
| Comparison Groups | 0.15 | |||
| Placebo | 17.5 (16.0, 21.0) | 38.0 (25.0, 45.0) | 16.0 (9.0, 29.0) | |
| Intervention | 17.0 (16.0, 19.0) | 50.0 (33.0, 64.0) | 31.0 (16.0, 45.0) | |
a Wilcoxon signed-rank test with Benjamini & Hochberg adjustment for multiple comparisons
b Mann‒Whitney U test with Benjamini‒Hochberg adjustment for multiple comparisons
Table 4.
Glasses duration stratified by the intervention arm (n = 29)
| Intervention (n = 15) | Placebo (n = 14) | p valuea | |
|---|---|---|---|
| Glasses Duration, median (IQR) | 7.5 (4.0, 14.0) | 7.5 (6.0, 14.0) | 0.89 |
a Mann‒Whitney U test
The glass duration during CAREN exposure did not significantly differ between the groups (p = 0.89) (Table 4 and Figs. 3 and 4).
Fig. 3.
Median MISC values prior to placebo or glasses intervention
Fig. 4.
Median MISC values following placebo or glasses intervention
Discussion
Principle findings
For this study, we had two principal findings, corresponding to each of the study’s aims. First, we observed that CAREN consistently induced motion sickness in all participants who were included in the data analysis, indicating that CAREN is a reliable way to reproduce motion sickness symptoms in a controlled environment. Second, the data suggest that the use of Hion™ motion sensitivity glasses did not decrease the severity of motion sickness symptoms, regardless of how long the glasses were worn. Although not significant, the results of the quantitative analysis revealed that the subjects in the placebo group had lower median post-MSAQ scores than did those who wore Hion™ glasses.
Comparison with current research
To our knowledge, this study is the first to document the use of CAREN to reproduce the symptoms of motion sickness. While CAREN has not been previously utilized for the purpose of inducing motion sickness, other studies have proven the efficacy of wearable virtual reality (VR) environments in eliciting motion sickness symptoms. Other studies have often referred to this type of motion sickness in the literature as “cybersickness” or “simulator sickness” as a subset of visually induced motion sickness. This may differ from the motion sickness experienced during the current study, due to the application of visual stimuli. In the present study, the CAREN used a semi-immersive system that did not completely block visual stimuli from reality, and a platform that induced motion throughout the simulation. Current literature defines cyber sickness as a type of motion sickness induced by visual stimuli that is usually absent from movement [18]. This creates a different type of sensory and vestibular mismatch than the current study. Based on this definition, we conclude that the CAREN system can induce motion sickness that is different from other virtual reality systems that may use full visual immersion and lack induced movement. We invite future research to compare these alternative types of motion sickness, and the possibility of a subcategory to motion sickness separate from cyber sickness as it relates to virtual reality and rehabilitation.
In comparison to existing literature using these glasses, the findings of the current study do not align with those reported by Camille de Thierry de Faletans et al., who reported a statistically significant difference in motion sickness symptoms between participants wearing glasses and the control group [19]. This discrepancy between the results of the current study, which was conducted with Hion™ glasses, and those of previous studies may be attributed to the relatively small sample size (29). In addition, a vastly different form of virtual reality than other studies that had the same or similar goals was used. Although the current study does not support claims by the manufacturer, it was unable to provide a statistically significant conclusion, calling for further research.
An additional consideration raised by the reviewer concerns Mal de Débarquement Syndrome (MdDS), a condition characterized by persistent sensations of self-motion following prolonged passive motion exposure. MdDS has been linked to maladaptation within the velocity storage mechanism of the vestibular system, which may prolong motion perception even after the motion stimulus has ceased. In the current study, participants’ exposure to the CAREN environment was brief and intermittent, and all motion sickness symptoms, as measured by the MSAQ, returned to near baseline levels within one hour of simulation termination. This rapid recovery suggests that the CAREN-induced motion did not produce prolonged vestibular maladaptation consistent with MdDS. Nevertheless, awareness of MdDS as a potential risk in more extended or repeated virtual motion exposures remains important for future research and clinical applications.
Strengths
A primary strength of this study is the use of CAREN, which affects both the visual and vestibular systems to create a more realistic and valid motion experience. Unlike other studies that rely solely on wearable visual systems, the semi-immersive environment provided by the CAREN enhances the authenticity of motion sickness induction, offering closer approximation to real-world stimuli. Methodologically, the implementation of a randomized control trial design strengthens the study by minimizing bias and increasing validity. The protocol was designed to be both straightforward and replicable for future studies. Additionally, continuous collection of motion sickness data at 60 s intervals via the MISC allowed for detailed tracking of symptom progression.
Limitations
One major limitation was the sample size of the study. While the number of participants was sufficient to run this pilot study, it was underpowered to detect small effect sizes potentially produced by Hion™ glasses. Therefore, we are limited in that the evidence suggests no decrease in the severity of motion sickness symptoms, rather than demonstrating no definitive effect of decreasing motion sickness symptoms.
Another limitation that should be considered is the lack of a dedicated anxiety questionnaire. Although the MSAQ is a multidimensional measure that does include anxiety-themed questions, it does not focus solely on anxiety; therefore, future studies should implement the addition of anxiety-specific questionnaires to isolate any effects that anxiety can have on motion sickness.
The Hion™ brand claims that their product works using an artificial horizon produced by fluid-filled glasses. Once a person experiences motion sickness, they should use the product in addition to staring at a stationary object for up to 14 min. Our study mimicked the company’s methods; however, we did not explicitly instruct participants to stare at a stationary object once the glasses were used but rather instructed them to keep their eyes open for the remainder of the CAREN simulation. Owing to the structural design of the CAREN and the simulation of a theme park ride on a semicircular digital screen, we were unable to provide participants with a stationary object within their visual field. Providing an object outside the visual field threatens to disrupt the effectiveness of the simulation; therefore, we elected to not provide an object. This discrepancy may have affected our study results, as we did not explicitly copy the company’s methodology.
While exploring sex differences would be of interest, our study was not designed with sufficient power to support such subgroup analyses. We powered our study to detect a medium effect size (Cohen’s d = 0.5) for paired analyses, and a large effect size (Cohen’s d = 1.0) for between-group comparisons, with 80% power at a significance level of 0.05. Although the distribution of male and female participants was approximately balanced across groups, dividing the sample further would result in insufficient power—only allowing us to detect very large effects (Cohen’s d ≥ 1.5). We were concerned that performing underpowered hypothesis tests could lead to uninterpretable or misleading results and thus elected not to conduct sex-specific analyses in this study.
Finally, although the collection of posturography data was considered during study design, it was ultimately excluded due to the complexity that the movement of the motion base adds to the data. Because the platform translated and rotated throughout the simulation, isolating the participants’ postural adjustments from the larger platform-induced forces was deemed infeasible for the scope of this project. Future studies using fixed-base or instrumented flooring systems may be better suited to capture meaningful postural control data during semi-immersive motion simulations.
Clinical implications
The findings of this study have demonstrated the ability of CAREN to recreate symptoms of motion sickness. However, the implications for both parts of this study highlight the need for further research. Further research using Hion™ glasses is recommended to increase the sample size (compared with the sample size in this study), which may lead to a statistically significant outcome for Hion™ glasses.
Although our data suggest that CAREN is effective at inducing motion sickness symptoms, it may represent only a narrow application of stimuli that cause motion sickness symptoms. The simulation we created, which replicated an amusement park ride, indeed caused motion sickness. However, a myriad of other stimuli can generate motion sickness. As previously discussed, motion sickness symptoms can arise from any situation where an individual’s eyes, inner ear, and body send conflicting signals to the brain, with notable examples that include traveling, virtual reality immersion, and amusement park rides. The CAREN excelled in delivering a standardized motion sickness-inducing experience. Further research should be conducted to evaluate the efficacy of fluid-filled glasses in other realistic motion sickness-inducing experiences, such as traveling in a car or standing on the deck of a boat, for applicability to daily life.
Conclusion
While our findings for the efficacy of motion sickness glasses did not reach statistical significance, they do suggest notable trends for the future direction of further research. As previously discussed, given the small sample size of this pilot study, we acknowledge the possibility that this study was underpowered to detect an effect, if one exists. However, the results from our study suggest that compared with placebo, fluid-filled peripheral glasses may not be as effective at reducing motion sickness symptoms.
This is particularly interesting considering the literature, which emphasizes the role of peripheral visual motion in contributing to motion sickness. One interpretation is that the fluid may simply be too weak of a stimulus to counteract the sensory mismatch that triggers symptoms. In other words, passive visual input might not be sufficient to override the body’s vestibular signals during motion and minimize discrepancies between VOR and perceived movement.
From an optometric standpoint, this depicts a potential gap in how we currently think about visual interventions. Optometry often focuses on central vision, acuity, and corrective lenses, but this study highlights a growing need to consider peripheral vision and its role in sensory integration, especially in environments where visual and vestibular cues are at odds. Although Hion™ glasses may not be effective, this research could inspire the development of new optical devices or therapies that are more actively involved in regulating visual-vestibular input as a form of functional vision therapy for motion sensitivity.
The current study concludes that CAREN offers a unique opportunity to simulate motion sickness symptoms in a controlled, highly reproducible environment, enabling the evaluation of such interventions. Given the prevalence and impact of motion sickness across various modes of travel, there is a clear need for effective, accessible, and nonpharmacological treatment options. Future research utilizing the CAREN platform can play a critical role in identifying and validating nonpharmaceutical solutions that are both practical and widely applicable for motion sickness management. Moreover, the CAREN can be utilized for rehabilitation purposes, such as evaluation, intervention, and treatment for motion sickness, as a standardized safe practice.
Acknowledgements
We thank the individuals that volunteered to participate in our study. Furthermore, we would like to thank the Midwestern University Therapy Institute for allowing the use of the CAREN for this study. We would also like to thank Shellee Diggs our clinical research coordinator for her organization and overall contributions to help this study run smoothly.
Abbreviations
- CAREN
Computer-Assisted Rehabilitation Environment
- ED
Emergency Department
- EOM
Extra Ocular Muscle
- FOV
Field of View
- MISC
Motion Illness Symptoms Classification
- MLF
Medial Longitudinal Fasciculus
- MSAQ
Motion Sickness Assessment Questionnaire
- MSSQ-SF
Motion Sickness Symptoms Questionnaire Short Form
- PPRF
Paramedian Pontine Reticular Formation
- VOR
Vestibulo-Ocular Reflex
- VR
Virtual Reality
Author contributions
Celeste Delap: Conceptualization, Methodology, Writing – Review & Edit, Supervision, Resources. Megan Germansky, Kendall Clark, Josh Himes, Angel Islas, and Samuel Bliese: Conceptualization, Methodology, Investigation, Project Administration, Writing – Original draft, Writing – Review and Editing. Jared Denton: Writing – Original draft, Writing – Review and Editing. Daniel DeBarr: Conceptualization, Methodology, Writing – Review and Edit, Investigation, Project Administration. Christina Esposito: Supervision. William Denton: CAREN Operation and Programing. Chase Irwin: Data curation and formal analysis.
Funding
Not applicable.
Data availability
The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.
Declarations
Ethics approval and consent to participate
This study was approved by the Midwestern University Institutional Review Board (IRB-24-0155). All procedures followed were in accordance with the institutional review boards ethical standards. All subjects consented to participate during the selection process.
Consent for publication
Not Applicable.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Lackner JR. Motion sickness: more than nausea and vomiting. Exp Brain Res. 2014;232(8):2493–510. 10.1007/s00221-014-4008-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Guo Y, Zhang Z, Zhang J, et al. Susceptibility to motion sickness during different types of vehicular travel. J Travel Med. 2019;26(8):taz058. 10.1093/jtm/taz058. [DOI] [PubMed] [Google Scholar]
- 3.Turner M, Griffin MJ. Motion sickness in public road transport: the effect of driver, route, and vehicle. Aviat Space Environ Med. 2001;72(6):469–75. PMID: 11439716. [Google Scholar]
- 4.UC Davis Health. Motion sickness: how you can prevent symptoms and enjoy travel. 2024. https://health.ucdavis.edu/blog/cultivating-health/motion-sickness-how-you-can-prevent-symptoms-and-enjoy-travel/2024/05
- 5.Cheung B, Hofer K. Lack of retention of adaptation to air sickness in student pilots. Mil Med. 2015;180(11):1135–8. 10.7205/MILMED-D-14-00441.26540704 [Google Scholar]
- 6.Ugur E, Konukseven BO, Topdag M, Cakmakci ME, Topdag DO. Expansion to the motion sickness susceptibility questionnaire-short form: a cross-sectional study. J Audiol Otol. 2022;26(2):76–82. 10.7874/jao.2021.00577. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Cohen B, Dai M, Yakushin SB, Cho C. The neural basis of motion sickness. J Neurophysiol. 2019;121(3):973–82. [DOI] [PubMed] [Google Scholar]
- 8.Lim YH, Kim JS, Lee HW, Kim SH. Postural instability induced by visual motion stimuli in patients with vestibular migraine. Front Neurol. 2018;9(433). 10.3389/fneur.2018.00433. [DOI] [PMC free article] [PubMed]
- 9.Beadle KL, Helbling AR, Love SL, April MD, Hunter CJ. Isopropyl alcohol nasal inhalation for nausea in the emergency department: a randomized controlled trial. Ann Emerg Med. 2016;68(1):1–e91. 10.1016/j.annemergmed.2015.09.031. [DOI] [PubMed] [Google Scholar]
- 10.Veldhuis P, Melse M, Mullaart N. Implementation of isopropyl alcohol (IPA) inhalation as the first-line treatment for nausea in the emergency department: practical advantages and influence on the quality of care. Int J Emerg Med. 2021;14:15. 10.1186/s12245-021-00334-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Lien HC, Sun WM, Chen YH, Kim H, Hasler W, Owyang C. Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular Vection. Am J Physiol Gastrointest Liver Physiol. 2003;284(3):G481–9. 10.1152/ajpgi.00164.2002. [DOI] [PubMed] [Google Scholar]
- 12.Flanagan MB, May JG, Dobie TG. Optokinetic nystagmus, vection, and motion sickness. Aviat Space Environ Med. 2002;73(11):1067–73. [PubMed] [Google Scholar]
- 13.Keshner EA, Weiss PT, Geifman D, Raban D. Tracking the evolution of virtual reality applications to rehabilitation as a field of study. J Neuroeng Rehabil. 2019;16(1). 10.1186/s12984-019-0552-6. [DOI] [PMC free article] [PubMed]
- 14.Gianaros PJ, Muth ER, Mordkoff JT, Levine ME, Stern RM. A questionnaire for the assessment of the multiple dimensions of motion sickness. Aviat Space Environ Med. 2001;72(2):115–9. [PMC free article] [PubMed] [Google Scholar]
- 15.Czeisler MÉ, Pruski JM, Wang P et al. Validation of the motion sickness severity scale: Secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness. PLoS One. 2023;18(1): e0280058. 10.1371/journal.pone.0280058 [DOI] [PMC free article] [PubMed]
- 16.de Winkel KN, Irmak T, Kotian V, Pool DM, Happee R. Relating individual motion sickness levels to subjective discomfort ratings. Exp Brain Res. 2022;240(4):1231–40. 10.1007/s00221-022-06334-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Irmak T, Pool DM, Happee R. Objective and subjective responses to motion sickness: the group and the individual. Exp Brain Res. 2021;239(2):515–31. 10.1007/s00221-020-05986-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Laessoe U, Abrahamsen S, Zepernick S, Raunsbaek A, Stensen C. Motion sickness and cybersickness - Sensory mismatch. Physiol Behav. 2023;258:114015. 10.1016/j.physbeh.2022.114015. [DOI] [PubMed] [Google Scholar]
- 19.Camille de Thierry de Faletans, Misericordia M, Vallier J-M, Duché P, Watelain E. Seasickness and partial peripheral vision obstruction with versus without an artificial horizon. Displays. 2024. https://www.sciencedirect.com/science/article/pii/S0141938224002154. Accessed 30 Apr 2025.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.



